2M3HBA Deficiency
Other Names
HSD10 disease
2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency
MHBD deficiency
hydroxyl-CoA dehydrogenase deficiency
3-hydroxy-2-methylbutyryl-CoA dehydrogenase (3H2MBD) deficiency
2-methyl-3-hydroxybutyric acidemia
Screening
Overview
Deficiency of this mitochondrial enzyme results in impaired oxidation of certain fatty acids and isoleucine, with resultant accumulation of organic acids.Incidence
The condition is very rare, occurring in fewer than 1 in 1 million people. HSD10 Disease (MedlinePlus) The mutation has been identified in 17 families. [Zschocke: 2012]Prenatal Testing
DNA testing is possible by amniocentesis or chorionic villus sampling (CVS) if the disease-causing mutation of an affected family member has been identified. Enzyme testing is possible by amniocentesis or CVS.Other Testing
Genetic testing is possible for at-risk family members if both disease causing mutations of an affected family member have been identified.Clinical Characteristics
With treatment, deterioration may be avoided, and some improvement may result. Without treatment, progressive loss of skills and neurologic impairment, mental retardation and seizures can be expected. Symptom onset has generally been between 9 and 14 months and may be aggravated by stress or illness.Initial signs/symptoms may include:
- Poor feeding
- Spasticity
- Lethargy
- Lab findings:
- Lactic acidosis
- Choreoathetosis
- Progressive loss of motor skills
- Hearing loss
- Retinal degeneration
- Seizures
- Brain damage
- Death
Follow-up Testing after Positive Screen
Quantitative plasma acylcarnitine profile, urine organic acids, enzyme assay in fibroblasts.Primary Care Management
Upon Notification of the + Screen
- Contact the family and evaluate the infant for poor feeding, vomiting, or lethargy.
- Provide emergency treatment/referral for symptoms of hypoglycemia, metabolic acdosis, or seizures.
- To confirm the diagnosis, work with the following service(s): Newborn Screening Services (see NM providers [2]).
- For evaluation and ongoing collaborative management, consult the following service(s): Pediatric Genetics (see NM providers [4]).
If the Diagnosis is Confirmed
- Educate the family regarding signs, symptoms, and the need for urgent care when the infant becomes ill.
- Isoleucine and protein restriction, treatment of acute episodes with glucose and fluids.
- For those identified after irreversible consequences, assist in management, particularly with low vision aids, hearing aids or cochlear implants, developmental and educational interventions.
Specialty Care Collaboration
Initial consultation and ongoing collaboration, particularly for dietary management. Genetic counseling for the family.Resources
Information & Support
For Professionals
Newborn Screening ACT Sheets & Confirmatory Algorithms (ACMG)
ACTion (ACT) Sheets and algorithms for responding to positive newborn screening test results, membership required; American
College of Medical Genetics.
2-methyl-3-hydroxybutyric aciduria (GARD)
Information and more links related to 2-methyl-3-hydroxybutyric aciduria, from the Genetic and Rare Diseases Information Center,
National Institutes of Health.
Resources for 2M3HBA Deficiency (Disease InfoSearch)
Compilation of information, articles, research, case studies, and genetics links; from Genetic Alliance.
2M3HBA Deficiency (OMIM)
Extensive review of literature providing technical information for providers on genetic disorders; Online Mendelian Inheritance
in Man site, hosted by Johns Hopkins University.
Genetics in Primary Care Institute (AAP)
Contains health supervision guidelines and other useful resources for the care of children with genetic disorders; American
Academy of Pediatrics.
For Parents and Patients
Support
Organic Acidemia Association (OAA)
A nonprofit organization that provides information, support, events, connections with other parents, a discussion board,
and nutrition and recipe ideas.
General
HSD10 Disease (MedlinePlus)
Excellent, detailed review of condition for patients and families; National Library of Medicine and National Institutes of
Health.
Tools
ACT Sheet for Elevated C5-OH Acylcarnitine (ACMG) (
400 KB)
Contains short-term recommendations for clinical follow-up of the newborn who has screened positive; American College of Medical
Genetics.
Services for Patients & Families in New Mexico (NM)
| Service Categories | # of providers* in: | NM | NW | Other states (5) (show) | | ID | MT | NV | RI | UT |
|---|---|---|---|---|---|---|---|---|---|---|
| Newborn Screening Services | 2 | 1 | 22 | 4 | 2 | 1 | 3 | |||
| Pediatric Genetics | 4 | 1 | 3 | 7 | 5 | 4 | 7 | |||
For services not listed above, browse our Services categories or search our database.
* number of provider listings may vary by how states categorize services, whether providers are listed by organization or individual, how services are organized in the state, and other factors; Nationwide (NW) providers are generally limited to web-based services, provider locator services, and organizations that serve children from across the nation.
Page Bibliography
Zschocke J.
HSD10 disease: clinical consequences of mutations in the HSD17B10 gene.
J Inherit Metab Dis.
2012;35(1):81-9.
PubMed abstract